Literature DB >> 17339601

Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?

Wenqing Gao1, James T Dalton.   

Abstract

Selective Androgen Receptor Modulators (SARMs) are a novel class of AR ligands that possess tissue-selective pharmacological activities. SARMs of various chemical structures have been discovered and characterized, and lead compounds with much improved specificity for AR, in vivo pharmacokinetic profiles, and higher degree of tissue selectivity have entered clinical development, and are expected to dramatically expand the clinical applications of androgens. With the rapid progress in SARM discovery and increasing demand for mechanism-based drug design, more and more research efforts have been devoted to the mechanisms of action of the observed tissue selectivity of SARMs. There is increasing enthusiasm in adapting the molecular mechanisms of action from SERM research to the SARM field; however, is the SARM story really so complicated? The tissue-specific expression of 5alpha-reductase might provide a simple explanation for this puzzle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339601      PMCID: PMC2040232          DOI: 10.1124/mi.7.1.3

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  22 in total

Review 1.  Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.

Authors:  A Negro-Vilar
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

Review 2.  Non-steroidal steroid receptor modulators.

Authors:  Rogier C Buijsman; Pedro H H Hermkens; Rachel D van Rijn; H Thijs Stock; N Miranda Teerhuis
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

3.  Discovery of nonsteroidal androgens.

Authors:  J T Dalton; A Mukherjee; Z Zhu; L Kirkovsky; D D Miller
Journal:  Biochem Biophys Res Commun       Date:  1998-03-06       Impact factor: 3.575

4.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

Review 5.  Design of antiandrogens and their mechanisms of action: a case study (anandron).

Authors:  J P Raynaud; J Fiet; J M Le Goff; P M Martin; M Moguilewsky; T Ojasoo
Journal:  Horm Res       Date:  1987

6.  Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.

Authors:  A S Wright; R C Douglas; L N Thomas; C B Lazier; R S Rittmaster
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

7.  Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.

Authors:  A M Brodie; C Son; D A King; K M Meyer; S E Inkster
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

8.  Pharmacodynamics of selective androgen receptor modulators.

Authors:  Donghua Yin; Wenqing Gao; Jeffrey D Kearbey; Huiping Xu; Kiwon Chung; Yali He; Craig A Marhefka; Karen A Veverka; Duane D Miller; James T Dalton
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

9.  New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.

Authors:  J P Edwards; S J West; C L Pooley; K B Marschke; L J Farmer; T K Jones
Journal:  Bioorg Med Chem Lett       Date:  1998-04-07       Impact factor: 2.823

10.  Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis.

Authors:  Keigo Hanada; Kazuyuki Furuya; Noriko Yamamoto; Hiroaki Nejishima; Kiyonoshin Ichikawa; Tsutomu Nakamura; Motonori Miyakawa; Seiji Amano; Yuji Sumita; Nao Oguro
Journal:  Biol Pharm Bull       Date:  2003-11       Impact factor: 2.233

View more
  12 in total

Review 1.  Sarcopenia: diagnosis and treatment.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

Review 2.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

3.  Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.

Authors:  Chris P Miller; Maysoun Shomali; C Richard Lyttle; Louis St L O'Dea; Hillary Herendeen; Kyla Gallacher; Dottie Paquin; Dennis R Compton; Bishwabhusan Sahoo; Sean A Kerrigan; Matthew S Burge; Michael Nickels; Jennifer L Green; John A Katzenellenbogen; Alexei Tchesnokov; Gary Hattersley
Journal:  ACS Med Chem Lett       Date:  2010-12-02       Impact factor: 4.345

4.  Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Authors:  Stephanie T Page; Lianne Hirano; Janet Gilchriest; Manjiri Dighe; John K Amory; Brett T Marck; Alvin M Matsumoto
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

Review 5.  Development of selective androgen receptor modulators (SARMs).

Authors:  Ramesh Narayanan; Christopher C Coss; James T Dalton
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

6.  The long and winding road for selective androgen receptor modulators.

Authors:  James T Dalton
Journal:  Br J Clin Pharmacol       Date:  2017-07-17       Impact factor: 4.335

7.  17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.

Authors:  Joshua F Yarrow; Christine F Conover; Sean C McCoy; Judyta A Lipinska; Cesar A Santillana; John M Hance; Darryl F Cannady; Tisha D VanPelt; Joshua Sanchez; Bryan P Conrad; Jennifer E Pingel; Thomas J Wronski; Stephen E Borst
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-25       Impact factor: 4.310

8.  Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.

Authors:  Barbara J Attardi; Stephanie T Page; Sheri A Hild; Christopher C Coss; Alvin M Matsumoto
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-24       Impact factor: 4.292

Review 9.  Pharmacology of anabolic steroids.

Authors:  A T Kicman
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 10.  New selective estrogen and androgen receptor modulators.

Authors:  Bart L Clarke; Sundeep Khosla
Journal:  Curr Opin Rheumatol       Date:  2009-07       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.